Teppei Komatsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Teppei Komatsu has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Yasuyuki Iguchi
Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan
23 shared publicationsHidetaka Mitsumura
Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan
18 shared publications- Yasuyuki Iguchi
Department of Neurology The Jikei University School of Medicine Tokyo Japan
12 shared publications Kenichiro Sakai
Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan
11 shared publications- Kenichi Sakuta
Department of Neurology, The Jikei University School of Medicine. Tokyo, Japan
8 shared publications Tomomichi Kitagawa
Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan
8 shared publications
Latest Publications
- 13 October 2026
- Published by Springer Nature in Journal of Human Hypertension
- p. 1-11
Joint association of growth hormone and cerebral small vessel disease with antihypertensive treatment burden after stroke: an exploratory prospective study
Growth hormone (GH) and cerebral small vessel disease (SVD) may influence blood pressure regulation. This study investigated the individual and joint associations of GH and SVD severity with antihypertensive management following stroke. We prospectively enrolled patients admitted for acute stroke between October 2020 and December 2022. Patients with pre-existing or newly diagnosed hypertension during the initial hospitalization were included. We examined whether baseline GH levels and severe SVD burden (total SVD score ≥2) during the index hospitalization were associated with high antihypertensive medication burden defined as the use of ≥2 antihypertensive agents, as well as with high antihypertensive treatment intensity using an antihypertensive treatment intensity score (TIS) ≥ 1 at 12 months post-stroke. Among 171 registered patients, 129 were included (107 ischemic stroke/transient ischemic attack and 22 intracerebral hemorrhage; median age, 60 years; 95 male). High antihypertensive medication burden at 12 months was observed in 19 patients (15%). Elevated GH levels (≥0.49 ng/mL) and severe SVD burden were independently associated with high antihypertensive medication burden and TIS ≥ 1. Moreover, the coexistence of elevated GH and severe SVD burden was significantly associated with high antihypertensive medication burden and TIS ≥ 1 compared with the absence of both factors. Elevated GH levels and severe SVD burden were independently associated with antihypertensive medication burden and treatment intensity 12 months after stroke. The combined presence was associated with both outcomes, suggesting a potential joint contribution of neuroendocrine and structural vascular factors to post-stroke blood pressure management.
- 13 October 2026
- Published by Springer Nature in Journal of Human Hypertension
- p. 1-11
Joint association of growth hormone and cerebral small vessel disease with antihypertensive treatment burden after stroke: an exploratory prospective study
Growth hormone (GH) and cerebral small vessel disease (SVD) may influence blood pressure regulation. This study investigated the individual and joint associations of GH and SVD severity with antihypertensive management following stroke. We prospectively enrolled patients admitted for acute stroke between October 2020 and December 2022. Patients with pre-existing or newly diagnosed hypertension during the initial hospitalization were included. We examined whether baseline GH levels and severe SVD burden (total SVD score ≥2) during the index hospitalization were associated with high antihypertensive medication burden defined as the use of ≥2 antihypertensive agents, as well as with high antihypertensive treatment intensity using an antihypertensive treatment intensity score (TIS) ≥ 1 at 12 months post-stroke. Among 171 registered patients, 129 were included (107 ischemic stroke/transient ischemic attack and 22 intracerebral hemorrhage; median age, 60 years; 95 male). High antihypertensive medication burden at 12 months was observed in 19 patients (15%). Elevated GH levels (≥0.49 ng/mL) and severe SVD burden were independently associated with high antihypertensive medication burden and TIS ≥ 1. Moreover, the coexistence of elevated GH and severe SVD burden was significantly associated with high antihypertensive medication burden and TIS ≥ 1 compared with the absence of both factors. Elevated GH levels and severe SVD burden were independently associated with antihypertensive medication burden and treatment intensity 12 months after stroke. The combined presence was associated with both outcomes, suggesting a potential joint contribution of neuroendocrine and structural vascular factors to post-stroke blood pressure management.
- Open Access
- 22 June 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (32) , e71199
Hydrogel Microtube Drug Carrier for Catheter‐Based Intravascular Therapy
This paper proposes the hydrogel microtube carrier that can be retained within blood vessels without interrupting blood flow for the practical application of intravascular therapy. The stable three‐dimensional network formed by the barium alginate gel enables the carrier to retain drugs within blood vessels. The utility of this hydrogel microtube carrier was confirmed through in vitro vascular mimic models and in vivo rat experiments. These experiments demonstrated that the hydrogel microtube carrier can be retained within blood vessels without obstructing blood flow and can deliver the drug model, Lipiodol, in the small renal artery. The hydrogel microtube carrier we propose represents a potential new platform advancing the practical application of intravascular drug delivery systems (DDS) and intravascular cell therapy.
- 22 June 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (32) , e71199
Open AccessHydrogel Microtube Drug Carrier for Catheter‐Based Intravascular Therapy
This paper proposes the hydrogel microtube carrier that can be retained within blood vessels without interrupting blood flow for the practical application of intravascular therapy. The stable three‐dimensional network formed by the barium alginate gel enables the carrier to retain drugs within blood vessels. The utility of this hydrogel microtube carrier was confirmed through in vitro vascular mimic models and in vivo rat experiments. These experiments demonstrated that the hydrogel microtube carrier can be retained within blood vessels without obstructing blood flow and can deliver the drug model, Lipiodol, in the small renal artery. The hydrogel microtube carrier we propose represents a potential new platform advancing the practical application of intravascular drug delivery systems (DDS) and intravascular cell therapy.
- Open Access
External Validation of Six Scores Differentiating Atherosclerotic vs. Embolic Large Vessel Occlusion
Purpose: Intracranial atherosclerotic disease-related large vessel occlusion (ICAD-LVO) presents distinct challenges, particularly regarding the high risk of reocclusion and the need for specific management strategies. While several prediction scores exist to differentiate ICAD-LVO from embolic LVO (EMB-LVO), their external validity remains unproven. We aimed to externally validate six established prediction scores for differentiating the two. Methods: We analyzed data from a prospectively maintained, two-center stroke registry (June 2021–March 2025). Consecutive patients who underwent mechanical thrombectomy and had complete clinical and imaging data necessary for calculating six scores (ISAT, REMIT, ABC 2 D, ATHE, ICAS-LVO, and Score-ICAD) were included. LVO etiology was defined based on angiographic findings during endovascular treatment. The discriminative performance of each score was assessed using the area under the receiver operating characteristic curve (AUC). Results: Of 1,288 screened admissions, 91 patients met the inclusion criteria (ICAD-LVO, n = 18; embolic occlusion, n = 73). The AUCs (95% confidence interval) for differentiating etiology were: ISAT, 0.870 (0.664–1.000; P = 0.064); REMIT, 0.793 (0.676–0.911; P 2 D, 0.627 (0.504–0.751; P = 0.095); ATHE, 0.600 (0.451–0.749; P = 0.230); and ICAS-LVO, 0.465 (0.301–0.630; P = 0.650). Conclusion: In this external validation, REMIT demonstrated the most robust and statistically significant discrimination between ICAD-LVO and EMB-LVO. Overall, scores incorporating imaging features outperformed those relying on clinical variables. These findings support the concept that ICAD-LVO represents a distinct pathophysiological entity from embolic occlusion and that accurate mechanism inference requires comprehensive imaging assessment of intracranial atherosclerotic disease beyond the occlusion site.
Open AccessExternal Validation of Six Scores Differentiating Atherosclerotic vs. Embolic Large Vessel Occlusion
Purpose: Intracranial atherosclerotic disease-related large vessel occlusion (ICAD-LVO) presents distinct challenges, particularly regarding the high risk of reocclusion and the need for specific management strategies. While several prediction scores exist to differentiate ICAD-LVO from embolic LVO (EMB-LVO), their external validity remains unproven. We aimed to externally validate six established prediction scores for differentiating the two. Methods: We analyzed data from a prospectively maintained, two-center stroke registry (June 2021–March 2025). Consecutive patients who underwent mechanical thrombectomy and had complete clinical and imaging data necessary for calculating six scores (ISAT, REMIT, ABC 2 D, ATHE, ICAS-LVO, and Score-ICAD) were included. LVO etiology was defined based on angiographic findings during endovascular treatment. The discriminative performance of each score was assessed using the area under the receiver operating characteristic curve (AUC). Results: Of 1,288 screened admissions, 91 patients met the inclusion criteria (ICAD-LVO, n = 18; embolic occlusion, n = 73). The AUCs (95% confidence interval) for differentiating etiology were: ISAT, 0.870 (0.664–1.000; P = 0.064); REMIT, 0.793 (0.676–0.911; P 2 D, 0.627 (0.504–0.751; P = 0.095); ATHE, 0.600 (0.451–0.749; P = 0.230); and ICAS-LVO, 0.465 (0.301–0.630; P = 0.650). Conclusion: In this external validation, REMIT demonstrated the most robust and statistically significant discrimination between ICAD-LVO and EMB-LVO. Overall, scores incorporating imaging features outperformed those relying on clinical variables. These findings support the concept that ICAD-LVO represents a distinct pathophysiological entity from embolic occlusion and that accurate mechanism inference requires comprehensive imaging assessment of intracranial atherosclerotic disease beyond the occlusion site.
- 13 December 2025
- Published by Elsevier in Journal of Cardiology
- Vol. 87 (5) , 434-439
Nonstenotic carotid artery plaque in patients with cryptogenic stroke after ICM: A sub-analysis of the LOOK study
- 13 December 2025
- Published by Elsevier in Journal of Cardiology
- Vol. 87 (5) , 434-439
Nonstenotic carotid artery plaque in patients with cryptogenic stroke after ICM: A sub-analysis of the LOOK study
- 16 September 2025
- Published by Springer Nature in Neurological Sciences
- p. 1-7
The essential role of multimodal magnetic resonance imaging in diagnosing vertebrobasilar artery dissection
Introduction: Vertebrobasilar artery dissection (VBD) results from blood entering a tear in the intima of the vertebral artery (VA), basilar artery (BA), or their branches. T1-Sampling Perfection with Application-optimized Contrast using different flip angle Evolution (T1-SPACE) is a valuable tool for detecting intramural hematoma (IMH). Despite its potential, clinical adoption of susceptibility-weighted imaging (SWI) remains limited. This study aimed to clarify the usefulness of SWI and T1-SPACE for detecting IMH in VBD. Methods: Consecutive patients admitted with symptomatic VBD within 28 days of onset between November 2014 and September 2023 were retrospectively screened from the Jikei University School of Medicine Stroke Registry. Inclusion criteria were definitive VBD diagnosis based on Spontaneous Cervicocephalic Arterial Dissections Study criteria and simultaneous acquisition of SWI and T1-SPACE. IMH detectability was compared between the two sequences. Results: The study included 74 patients (52 males; median age, 45 years). IMH detection rates showed no significant difference between two sequences. The detection rate of IMH on SWI was relatively low in extracranial VA compared to intracranial VA or BA and PICA (3/8 vs. 62/66, p < 0.001), whereas on T1-SPACE, IMH was consistently detected in extracranial VA and intracranial VA or BA but was markedly lower in PICA (1/7 vs. 65/67, p < 0.001). Time from symptom onset to detection was similar across groups. Conclusions: SWI demonstrated limited sensitivity for detecting IMH in extracranial VA, whereas T1-SPACE was less effective in PICA. Considering the site-specific differences in the culprit vessel, the combined use of both sequences may enhance diagnostic accuracy.
- 16 September 2025
- Published by Springer Nature in Neurological Sciences
- p. 1-7
The essential role of multimodal magnetic resonance imaging in diagnosing vertebrobasilar artery dissection
Introduction: Vertebrobasilar artery dissection (VBD) results from blood entering a tear in the intima of the vertebral artery (VA), basilar artery (BA), or their branches. T1-Sampling Perfection with Application-optimized Contrast using different flip angle Evolution (T1-SPACE) is a valuable tool for detecting intramural hematoma (IMH). Despite its potential, clinical adoption of susceptibility-weighted imaging (SWI) remains limited. This study aimed to clarify the usefulness of SWI and T1-SPACE for detecting IMH in VBD. Methods: Consecutive patients admitted with symptomatic VBD within 28 days of onset between November 2014 and September 2023 were retrospectively screened from the Jikei University School of Medicine Stroke Registry. Inclusion criteria were definitive VBD diagnosis based on Spontaneous Cervicocephalic Arterial Dissections Study criteria and simultaneous acquisition of SWI and T1-SPACE. IMH detectability was compared between the two sequences. Results: The study included 74 patients (52 males; median age, 45 years). IMH detection rates showed no significant difference between two sequences. The detection rate of IMH on SWI was relatively low in extracranial VA compared to intracranial VA or BA and PICA (3/8 vs. 62/66, p < 0.001), whereas on T1-SPACE, IMH was consistently detected in extracranial VA and intracranial VA or BA but was markedly lower in PICA (1/7 vs. 65/67, p < 0.001). Time from symptom onset to detection was similar across groups. Conclusions: SWI demonstrated limited sensitivity for detecting IMH in extracranial VA, whereas T1-SPACE was less effective in PICA. Considering the site-specific differences in the culprit vessel, the combined use of both sequences may enhance diagnostic accuracy.
- Open Access
- 29 May 2025
- Published by Springer Nature in Egyptian Journal of Radiology and Nuclear Medicine
- Vol. 56 (1) , 1-3
Susceptibility-weighted imaging is a key diagnostic tool for isolated posterior inferior cerebellar arterial dissection: a case report
Background: The diagnosis of isolated posterior inferior cerebellar artery (PICA) dissection poses challenges because of the diminutive caliber and convoluted nature of these vessels. This report aimed to highlight the potential superiority of susceptibility-weighted imaging (SWI) in the early detection of intramural hematoma. Case presentation: We encountered a case of transient lateral medullary syndrome by isolated PICA dissection. The diagnosis was based on observation of chronological changes on magnetic resonance angiography and the appearance of subtle signal on T1-sampling perfection with application-optimized contrasts using different flip angle evolutions (T1-SPACE) in the proximal portion of the PICA. Intramural hematoma on SWI appeared earlier and was more conspicuous than signal changes seen on T1-SPACE. Conclusion: The standard diagnostic criteria for intracranial artery dissection do not include SWI findings; however, the present findings indicate that SWI may offer superior diagnostic efficacy to T1-SPACE, especially in the early stage and after the onset of isolated PICA dissection with a small amount of intramural hematoma.
- 29 May 2025
- Published by Springer Nature in Egyptian Journal of Radiology and Nuclear Medicine
- Vol. 56 (1) , 1-3
Open AccessSusceptibility-weighted imaging is a key diagnostic tool for isolated posterior inferior cerebellar arterial dissection: a case report
Background: The diagnosis of isolated posterior inferior cerebellar artery (PICA) dissection poses challenges because of the diminutive caliber and convoluted nature of these vessels. This report aimed to highlight the potential superiority of susceptibility-weighted imaging (SWI) in the early detection of intramural hematoma. Case presentation: We encountered a case of transient lateral medullary syndrome by isolated PICA dissection. The diagnosis was based on observation of chronological changes on magnetic resonance angiography and the appearance of subtle signal on T1-sampling perfection with application-optimized contrasts using different flip angle evolutions (T1-SPACE) in the proximal portion of the PICA. Intramural hematoma on SWI appeared earlier and was more conspicuous than signal changes seen on T1-SPACE. Conclusion: The standard diagnostic criteria for intracranial artery dissection do not include SWI findings; however, the present findings indicate that SWI may offer superior diagnostic efficacy to T1-SPACE, especially in the early stage and after the onset of isolated PICA dissection with a small amount of intramural hematoma.
- 5 March 2025
- Published by Wiley in Muscle & Nerve
- Vol. 71 (6) , 1132-1134
Sustained Minimal Manifestations With Extended Interval Dosing of Efgartigimod in Seronegative Myasthenia Gravis: Case Report
- 5 March 2025
- Published by Wiley in Muscle & Nerve
- Vol. 71 (6) , 1132-1134
Sustained Minimal Manifestations With Extended Interval Dosing of Efgartigimod in Seronegative Myasthenia Gravis: Case Report
- 4 March 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (3) , 1-4
Predictors of achieving minimal manifestations or better status in ocular myasthenia gravis with immunotherapy
Background Ocular myasthenia gravis (MG), while less severe than generalized MG, significantly impairs quality of life due to its impact on vision and daily activities. Immunotherapy is a key treatment, yet the optimal timing for initiation remains undefined. Objective To identify predictive factors for achieving minimal manifestations (MM) or better status in ocular MG patients receiving immunotherapy, with a focus on the role of early intervention. Methods We conducted a retrospective analysis of 48 ocular MG patients treated at our institution. Patients were categorized based on whether they achieved MM or better status. Clinical variables were analyzed using univariate, receiver-operating characteristic, and multivariate logistic regression analyses. Results MM or better status was achieved in 34/48 patients (median onset age: 55 years). Time from symptom onset to immunotherapy initiation was significantly shorter in those who achieved MM or better status (median: 30 days vs. 1095 days; p < 0.001). Receiver-operating characteristic analysis determined a 255-day cutoff for immunotherapy initiation, yielding sensitivity of 92.9% and specificity of 91.2% (AUC = 0.986, 95% CI: 0.962–1.000, p < 0.001). Logistic regression confirmed early immunotherapy as an independent predictor. Conclusions Early initiation of immunotherapy (< 255 days from onset) significantly improves the likelihood of achieving MM or better status in ocular MG. These findings support the need for prompt diagnosis and treatment to optimize outcomes.
- 4 March 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (3) , 1-4
Predictors of achieving minimal manifestations or better status in ocular myasthenia gravis with immunotherapy
Background Ocular myasthenia gravis (MG), while less severe than generalized MG, significantly impairs quality of life due to its impact on vision and daily activities. Immunotherapy is a key treatment, yet the optimal timing for initiation remains undefined. Objective To identify predictive factors for achieving minimal manifestations (MM) or better status in ocular MG patients receiving immunotherapy, with a focus on the role of early intervention. Methods We conducted a retrospective analysis of 48 ocular MG patients treated at our institution. Patients were categorized based on whether they achieved MM or better status. Clinical variables were analyzed using univariate, receiver-operating characteristic, and multivariate logistic regression analyses. Results MM or better status was achieved in 34/48 patients (median onset age: 55 years). Time from symptom onset to immunotherapy initiation was significantly shorter in those who achieved MM or better status (median: 30 days vs. 1095 days; p < 0.001). Receiver-operating characteristic analysis determined a 255-day cutoff for immunotherapy initiation, yielding sensitivity of 92.9% and specificity of 91.2% (AUC = 0.986, 95% CI: 0.962–1.000, p < 0.001). Logistic regression confirmed early immunotherapy as an independent predictor. Conclusions Early initiation of immunotherapy (< 255 days from onset) significantly improves the likelihood of achieving MM or better status in ocular MG. These findings support the need for prompt diagnosis and treatment to optimize outcomes.
- 21 February 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 250, 108794
Sleep disturbance is associated with worsening quality of life in patients with multiple system atrophy
- 21 February 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 250, 108794
Sleep disturbance is associated with worsening quality of life in patients with multiple system atrophy
- 19 November 2024
- Published by Springer Nature in Translational Stroke Research
- Vol. 16 (4) , 1331-1339
Novel Rat Model of Embolic Cerebral Ischemia Using a Radiopaque Blood Clot and a Microcatheter Under Fluoroscopy
Conventional rat models of thromboembolic stroke do not allow control of infarct size or spontaneous recanalization. We aimed to develop a novel rat thromboembolic stroke model that ensures highly reproducible infarct sizes and locations within the MCA territory and does not require arterial ligation. Twenty male Sprague–Dawley rats and two sham-operated rats were included. A microcatheter was navigated from the caudal ventral artery to the internal carotid artery using digital subtraction angiography. A blood clot (diameter, 0.86 mm; length, 3 mm) containing zirconium dioxide was advanced in the catheter. Fluoroscopy was performed at 1, 3, 6, and 24 h after stroke model creation, and TTC staining was conducted at 24 h. Neurological deficit scores were measured. In all embolized rats, the ACA and MCA bifurcation were selective. Median operating time was 6 min. The position of the radiopaque blood clot remained unchanged for 24 h after model creation in 19/20 rats. Median infarct volume was 242 mm3 (IQR, 239–262 mm3). We present a novel rat model of highly reproducible focal infarct in only the MCA territory. Fluoroscopy effectively identified any blood clot migration. This model could contribute to the development of new thrombolytic agents.
- 19 November 2024
- Published by Springer Nature in Translational Stroke Research
- Vol. 16 (4) , 1331-1339
Novel Rat Model of Embolic Cerebral Ischemia Using a Radiopaque Blood Clot and a Microcatheter Under Fluoroscopy
Conventional rat models of thromboembolic stroke do not allow control of infarct size or spontaneous recanalization. We aimed to develop a novel rat thromboembolic stroke model that ensures highly reproducible infarct sizes and locations within the MCA territory and does not require arterial ligation. Twenty male Sprague–Dawley rats and two sham-operated rats were included. A microcatheter was navigated from the caudal ventral artery to the internal carotid artery using digital subtraction angiography. A blood clot (diameter, 0.86 mm; length, 3 mm) containing zirconium dioxide was advanced in the catheter. Fluoroscopy was performed at 1, 3, 6, and 24 h after stroke model creation, and TTC staining was conducted at 24 h. Neurological deficit scores were measured. In all embolized rats, the ACA and MCA bifurcation were selective. Median operating time was 6 min. The position of the radiopaque blood clot remained unchanged for 24 h after model creation in 19/20 rats. Median infarct volume was 242 mm3 (IQR, 239–262 mm3). We present a novel rat model of highly reproducible focal infarct in only the MCA territory. Fluoroscopy effectively identified any blood clot migration. This model could contribute to the development of new thrombolytic agents.